These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1087 related items for PubMed ID: 11161387

  • 1. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK.
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E.
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [Abstract] [Full Text] [Related]

  • 10. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP.
    J Clin Oncol; 2004 Mar 15; 22(6):1014-24. PubMed ID: 14981102
    [Abstract] [Full Text] [Related]

  • 11. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
    Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI.
    Br J Cancer; 2001 May 04; 84(9):1242-51. PubMed ID: 11336477
    [Abstract] [Full Text] [Related]

  • 12. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F.
    Cancer; 2004 Jun 01; 100(11):2367-75. PubMed ID: 15160340
    [Abstract] [Full Text] [Related]

  • 13. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H, Thymara I, Thomas-Tsagli E, Patsouris E.
    Hum Pathol; 2005 Aug 01; 36(8):899-907. PubMed ID: 16112007
    [Abstract] [Full Text] [Related]

  • 14. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M.
    Hepatology; 1999 Jul 01; 30(1):90-9. PubMed ID: 10385644
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
    Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ.
    J Clin Oncol; 2004 Mar 15; 22(6):1007-13. PubMed ID: 14981105
    [Abstract] [Full Text] [Related]

  • 17. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E, Peschos D, Goussia A, Mittari E, Charalabopoulos K, Michael M, Salmas M, Vougiouklakis T, Assimakopoulos D, Agnantis NJ.
    J Exp Clin Cancer Res; 2004 Jun 15; 23(2):277-83. PubMed ID: 15354413
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
    Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM.
    Clin Cancer Res; 2004 Aug 01; 10(15):5168-77. PubMed ID: 15297421
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.